`Date filed: December 19, 2017
`
`Filed On Behalf Of:
`Novartis AG
`
`By:
`Nicholas N. Kallas
`NKallas@fchs.com
`ZortressAfinitorIPR@fchs.com
`(212) 218-2100
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`PAR PHARMACEUTICAL, INC.,
`ARGENTUM PHARMACEUTICAL LLC, AND
`WEST-WARD PHARMACEUTICALS
`INTERNATIONAL LIMITED
`Petitioners,
`
`v.
`
`NOVARTIS AG,
`Patent Owner.
`
`
`
`
`Case IPR2016-014791
`Patent No. 9,006,224
`
`
`
`
`PATENT OWNER’S EXHIBIT LIST 10
`
`
`
`
`1 Argentum Pharmaceutical LLC was joined as a party to this proceeding via a
`Motion for Joinder in IPR2017-01063; West-Ward Pharmaceuticals International
`Limited was joined as a party via a Motion for Joinder in IPR2017-01078.
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2001
`
`Expert Declaration Of Matthew H. Kulke,
`M.D., M.M.Sc. (November 18, 2016)
`
`Kulke Decl.
`
`2002
`
`Curriculum Vitae of Matthew H. Kulke,
`M.D., M.M.Sc. (May 20, 2016)
`
`Kulke C.V.
`
`2003
`
`Seeley, R. R., Stephens, T.D., & Tate, P.,
`Anatomy & Physiology, 3rd Edition,
`pages 585 – 586 (1995)
`
`2004
`
`Reserved
`
`Seeley
`
`
`
`2005
`
`Laughlin, E.H., Coming To Terms With
`Cancer: A Glossary Of Cancer-Related
`Terms, page 4 (2002)
`
`Laughlin
`Cancer Glossary
`
`2006
`
` Reserved
`
`2007
`
` Reserved
`
`2008
`
`Motzer, R.J. & Russo, P., “Systemic
`Therapy For Renal Cell Carcinoma,” J.
`Urology 163:408-417 (2000)
`
`2009
`
` Reserved
`
`2010
`
`Pazdur, R., et al. (eds.), Chapters 6, 11,
`14-16, 19, 25, Cancer Management: A
`Multidisciplinary Approach: Medical,
`Surgical, & Radiation Oncology, 9th
`Edition (2005)
`
`1
`
`
`
`
`
`Motzer
`
`
`
`Pazdur
`
`
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Kouvaraki, M.A. et al., “Fluorouracil,
`Doxorubicin, And Streptozocin In The
`Treatment Of Patients With Locally
`Advanced And Metastatic Pancreatic
`Endocrine Carcinomas,” J. Clin. Oncol.
`22(23):4762-4771 (2004)
`
`Delaunoit, Th., et al., “The Doxorubicin-
`Streptozotocin Combination For The
`Treatment Of Advanced Well-
`Differentiated Pancreatic Endocrine
`Carcinoma: A Judicious Option?,” Eur. J.
`Cancer 40:515-520 (2004)
`
`Kulke, M.H., Chapter 110,
`“Neuroendocrine Cancer,” Clinical
`Hematology and Oncology: Presentation,
`Diagnosis and Treatment (Furie, B., et al.
`eds. 2003)
`
`Kulke, M.H. et al., “A Phase II Trial Of
`Gemcitabine For Metastatic
`Neuroendocrine Tumors,” Cancer
`101(5): 934-939 (2004)
`
`Margolin, K. et al., “CCI-779 In
`Metastatic Melanoma: A Phase II Trial
`Of The California Cancer Consortium,”
`Cancer 104(5): 1045-1048 (2005)
`
`Kouvaraki
`
`Delaunoit
`
`Kulke 2003a
`
`Kulke 2004
`
`Margolin
`
`
`
`2
`
`
`
`2016
`
`“Novartis Drug Afinitor Is First
`Treatment For Advanced Pancreatic NET
`To Provide Overall Survival Of More
`Than 3.5 Years In Phase III Trial,”
`Novartis Institutes For Biomedical
`Research (September 27, 2014)
`
`Novartis Press
`Release
`
`2017
`
`Ritschel, W.A., Handbook of Basic
`Pharmacokinetics, 4th Edition, pages 6-7,
`264-267 (1992)
`
`Ritschel
`
`Heitz, Ph.U., et al., Chapter 4, “Tumours
`Of The Endocrine Pancreas,” World
`Health Organization Classification of
`Tumours, Pathology and Genetics,
`Tumours of Endocrine Organs, pages
`177-182 (DeLellis, R.A. et al., eds. 2004)
`
`WHO 2004
`
`Physicians’ Desk Reference, 59th Edition
`(2005), pages 1844-1849 (Entry for
`Gemzar® (Gemcitabine HCl))
`
`Gemzar®
`Prescribing
`Information 2005
`
`Kulke, M.H. & Mayer, R.J., “Carcinoid
`Tumors,” N. Eng. J. Med. 340(11): 858-
`868 (1999)
`
`Kulke 1999
`
`2018
`
`2019
`
`2020
`
`2021
`
`Gennaro, A.R. (Ed.), Remington’s, 18th
`Edition, pages 726-730 (1990)
`
`Remington’s
`
`2022
`
`Yao, J.C. et al., “Everolimus For
`Advanced Pancreatic Neuroendocrine
`Tumors,” N. Eng. J. Med. 364(6): 514-
`523 (2011)
`
`Yao 2011
`
`
`
`3
`
`
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`Kola, I. & Landis, J., “Can The
`Pharmaceutical Industry Reduce Attrition
`Rates?,” Nat. Rev. Drug Discov., 3:711-
`715 (2004)
`
`Kola & Landis
`
`Excerpts of Transcript of Trial Testimony
`of M. Ratain, Pfizer Inc. et al. v. Mylan
`Pharms. Inc., (C.A. No. 10-528-GMS),
`(D. Del. November 29, 2012), Pages 778-
`79, 950, 995
`
`Excerpts of Transcript of Trial Testimony
`of M. Ratain, Novartis v. Breckenridge,
`Roxane and Par (C.A. Nos. 14-1043-
`RGA, 14-1196-RGA and 14-1289-RGA)
`(D. Del. August 31, 2016), Pages 769-
`772, 957, 993-94, 1003, 1010, 1012, 1014
`
`Excerpts of Transcript of Deposition of
`M. Ratain, Novartis v. Breckenridge,
`Roxane and Par (C.A. Nos. 14-1043-
`RGA, 14-1196-RGA and 14-1289-RGA)
`(D. Del. Apr. 11, 2016), Pages 1-5, 34,
`156, 340
`
`Dancey, J.E., “Inhibitors Of The
`Mammalian Target Of Rapamycin,”
`Expert Opin. Investig. Drugs 14(3): 313-
`328 (2005)
`
`Duran, I, et al., “A Phase II Clinical And
`Pharmacodynamic Study Of
`Temsirolimus In Advanced
`Neuroendocrine Carcinomas,” British J.
`of Cancer 95(9): 1148-1154 (2006)
`
`Ratain Trial Tr. I
`
`Ratain Trial Tr. II
`
`Ratain Dep. Tr. I
`
`Dancey 2005
`
`Duran 2006
`
`
`
`4
`
`
`
`2029
`(served
`but not
`filed)
`
`Declaration of Nicholas N. Kallas
`Regarding Exhibits 2016, 2022, And
`2028
`
`2030
`(served
`but not
`filed)
`
`The New England Journal of Medicine,
`Publication Process, available at
`http://www.nejm.org/page/media-
`center/publication-process
`
`2031
`(served
`but not
`filed)
`
`British Journal of Cancer, Aims and
`Scope, available at
`http://www.nature.com/bjc/about/aims_sc
`ope.html
`
`2032
`(served
`but not
`filed)
`
`Transcript of Trial Testimony of M.
`Ratain, Pfizer Inc. et al. v. Mylan
`Pharms. Inc., (C.A. No. 10-528-GMS),
`(D. Del. November 29, 2012)
`
`2033
`(served
`but not
`filed)
`
`Transcript of Trial Testimony of M.
`Ratain, Novartis v. Breckenridge, Roxane
`and Par (C.A. Nos. 14-1043-RGA, 14-
`1196-RGA and 14-1289-RGA) (D. Del.
`August 31, 2016)
`
`Transcript of Deposition of M. Ratain,
`Novartis v. Breckenridge, Roxane and
`Par (C.A. Nos. 14-1043-RGA, 14-1196-
`RGA and 14-1289-RGA) (D. Del. Apr.
`11, 2016)
`
`Declaration Of Julie Masow Pursuant to
`Fed. R. Evid. 902(11)
`
`2034
`(served
`but not
`filed)
`
`2035
`(served
`but not
`filed)
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2036
`
`Physicians’ Desk Reference, 58th Edition
`(2004), pages 1812-1817 (Entry for
`Gemzar®(Gemcitabine HCl))
`
`2004 PDR
`
`2037
`
`Declaration in Support of Patent Owner
`Novartis’s Motion for Pro Hac Vice
`Admission of Charlotte Jacobsen Under
`37 C.F.R. § 42.10
`
`
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`Longnecker, D.S. et al., “Transplantation
`of Azaserine-Induced Carcinomas Of
`Pancreas In Rats,” Cancer Letters, 7:197-
`202 (1979)
`
`Longnecker, D.S. & Curphey,T.J.,
`“Adenocarcinoma Of The Pancreas In
`Azaserine-Treated Rats,” Cancer Res.,
`35:2249-2258 (1975)
`
`Longnecker 1979
`
`Longnecker 1975
`
`Transcript Of The April 17, 2017
`Deposition Of Mark J. Ratain
`
`Ratain Tr.
`
`Expert Declaration Of Matthew H. Kulke,
`M.D., M.M.Sc. (May 11, 2017)
`
`Kulke
`
`Curriculum Vitae of Matthew H. Kulke,
`M.D., M.M.Sc. (February 1, 2017)
`
`Kulke 2017 C.V.
`
`Adjei, A.A., “Signal Transduction
`Pathway Targets For Anticancer Drug
`Discovery,” Current Pharm. Design 6(4):
`361-378 (2000)
`
`Adjei
`
`Afinitor® FDA Supplemental Approval
`Letter To Novartis Pharmaceuticals
`Corporation, dated May 5, 2011
`
`Afinitor® Supp.
`Approval Letter
`
`
`
`6
`
`
`
`2045
`
`2046
`
`2047
`
`2048
`
`2049
`
`2050
`
`2051
`
`Ansell, S.M., et al., “A Phase II Study Of
`High-Dose Paclitaxel In Patients With
`Advanced Neuroendocrine Tumors,”
`Cancer 91(8): 1543-48 (2001)
`
`Ansell, S.M., et al., “Topotecan In
`Patients With Advanced Neuroendocrine
`Tumors: A Phase II Study With
`Significant Hematologic Toxicity,” Am.
`J. Clin. Oncol. 27(3): 232-235 (2004)
`
`Bajetta, E., et al., “Treatment Of
`Metastatic Carcinoids And Other
`Neuroendocrine Tumors With
`Recombinant Interferon-Alpha-2a,”
`Cancer 72(10): 3099-3105 (1993)
`
`Bakker, W.H., et al., “In Vivo
`Application Of [111In-DTPA-D-Phe1]-
`Octreotide For Detection Of Somatostatin
`Receptor-Positive Tumors In Rats,” Life
`Sciences 49(22): 1593-1601 (1991)
`
`Carr, K., et al., “A Phase II Trial Of
`Imatinib In Patients With Advanced
`Carcinoid Tumor,” J. Clin. Oncol., ASCO
`Procs. 22: 14S (Abs. 4124) (July 15
`Supplement) (2004)
`
`Chang, S.M., et al., “Phase II Study Of
`CCI-779 In Patients With Recurrent
`Gliobstaoma Multiforme,” Investig. New
`Drugs 23(4): 357-361 (2005)
`
`Cheng, J.Q., et al., “The Akt/PKB
`Pathway: Molecular Target For Cancer
`Drug Discovery,” Oncogene 24: 7482-
`7492 (2005)
`
`Ansell 2001
`
`Ansell 2004
`
`Bajetta
`
`Bakker
`
`Carr
`
`Chang
`
`Cheng
`
`
`
`7
`
`
`
`2052
`
`2053
`
`2054
`
`2055
`
`2056
`
`Creaven, P.J. & Raghavan, D., Chapter 8,
`“Principles Of Chemotherapy For
`Genitourinary Cancer: Implications For
`Development Of New Anticancer Drugs,”
`Principles And Practice Of Genitourinary
`Oncology (Raghavan, D., et al. eds. 1997)
`
`Doran, H., et al., Chapter 1,
`“Epidemiology Of Pancreatic
`Neuroendocrine Tumours,” Pancreatic
`Disease: Basic Science And Clinical
`Management (Johnson, C.D. & Imrie,
`C.W. eds. 2004)
`
`Guidance For Industry: Clinical Trial
`Endpoints For The Approval Of Cancer
`Drugs And Biologics, US Department Of
`Health And Human Services, FDA 1-19
`(May 2007), available at
`http://www.fda.gov/downloads/Drugs/.../
`Guidances/ucm071590.pdf (accessed
`12/9/2016)
`
`Foster, B.J., et al., “A Strategy For The
`Development Of Two Clinically Active
`Cisplatin Analogs: CBDCA And
`CHIP,” Cancer Chemotherapy
`Pharmacology 25: 395-404 (1990)
`
`Hidalgo, M., et al., “A Phase I And
`Pharmacokinetic Study Of Temsirolimus
`(CCI-779) Administered Intravenously
`Daily For 5 Days Every 2 Weeks To
`Patients With Advanced Cancer,”
`Clinical Cancer Res. 12(19): 5755-5763
`(2006)
`
`Creaven
`
`Doran
`
`FDA Guidance
`
`Foster
`
`Hidalgo 2006
`
`
`
`8
`
`
`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`Jacobsen, W., et al., “Comparison Of The
`In Vitro Metabolism Of The Macrolide
`Immunosuppressants Sirolimus And
`RAD,” Transplant. Procs. 33: 514-515
`(2001)
`
`Kokkinakis, D.M., et al., “Role Of O6-
`Methylguanine-DNA Methyltransferase
`In The Resistance Of Pancreatic Tumors
`To DNA Alkylating Agents,” Cancer
`Research 57: 5360-5368 (1997)
`
`Kulke, M.H., “Recent Developments In
`The Pharmacological Treatment Of
`Advanced Pancreatic Cancer,” Expert
`Opin. Investig. Drugs 12(6): 983-992
`(2003)
`
`Jacobsen
`
`Kokkinakis
`
`Kulke 2003b
`
`Laughlin, E.H., Coming To Terms With
`Cancer: A Glossary Of Cancer-Related
`Terms, pages 157-159 (2002)
`
`Laughlin Cancer
`Glossary
`
`Marx, J., “Encouraging Results For
`Second-Generation Antiangiogenesis
`Drugs,” Science 308: 1248-1249 (2005)
`
`McStay, M. & Caplin, M.E., Chapter 4,
`“GI Hormone Producing Tumours:
`Syndromes And Treatment Options,”
`Pancreatic Disease: Basic Science And
`Clinical Management (Johnson, C.D. &
`Imrie, C.W. eds. 2004)
`
`Moertel, C.G., et al., “Treatment Of
`Neuroendcorine Carcinomas With
`Combined Etoposide And Cisplatin,”
`Cancer 68: 227-232 (1991)
`
`Marx
`
`McStay
`
`Moertel 1991
`
`
`
`9
`
`
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`Mossman, B.T., et al., “Chlorozocin: A
`Diabetogenic Analogue Of Streptozocin
`With Dissimilar Mechanisms Of Action
`On Pancreatic Beta Cells,” Diabetes 34:
`602-610 (1985)
`
`Motzer, R.J. & Vogelzang, N.J., Chapter
`85, “Chemotherapy For Renal Cell
`Carcinoma,” Principals And Practice
`Genitourinary Oncology (Raghavan, D.,
`et al. eds. 1997)
`
`Muggia, F.M. & Green, M.D., “New
`Anthracycline Antitumor
`Antibiotics,” Crit. Rev. Oncol./Hematol.
`11: 43-64 (1991)
`
`Pazdur, R., et al., “Phase II Trial Of
`Intravenous CI-980 (NSC 370147) In
`Patients With Metastatic Colorectal
`Carcinoma: Model For Prospective
`Evaluation Of Neurotoxicity,” Am. J.
`Clin. Oncol. 20(6): 573-576 (1997)
`
`Physicians’ Desk Reference, 67th Edition
`(2013), pages 2589-2594 (Entry for
`Torisel® (temsirolimus))
`
`Physicians’ Desk Reference, 46th Edition
`(1992), pages 2024-2027 (Entry for
`Sandimmune® (cyclosporin))
`
`Physicians’ Desk Reference, 49th Edition
`(1995), pages 2034-2036 (Entry for
`fluorouracil)
`
`Physicians’ Desk Reference, 54th Edition
`(2000), pages 881-887 (Entry for Taxol®
`(paclitaxel))
`
`Mossman
`
`Motzer &
`Vogelzang
`
`Muggia & Green
`
`Pazdur 1997
`
`2013 PDR
`
`1992 PDR
`
`1995 PDR
`
`2000 PDR
`
`
`
`10
`
`
`
`2072
`
`Physicians’ Desk Reference, 58th Edition
`(2004), pages 672-674 (Entry for Iressa®
`(gefitinib)), 894-896 (Entry for
`Adriamycin® (doxorubicin)), 1355-1358
`(Entry for Herceptin® (trastuzumab)),
`2268-2273 (Entry for Gleevec® (imatinib
`mesyate)), 2305-2311 (Entry for
`Sandostatin® (octreotide acetate)), 3483-
`3490 (Entry for Rapamune® (sirolimus))
`
`2004 PDR
`
`2073
`
`Physicians’ Desk Reference, 70th Edition
`(2016), pages 1652-1667 (Entry for
`Afinitor® (everolimus))
`
`2016 PDR
`
`2074
`
`Ramanathan, R.K., et al., “Phase II Trial
`Of Dacarbazine (DTIC) In Advanced
`Pancreatic Islet Cell Carcinoma. Study Of
`The Eastern Cooperative Oncology
`Group-E6282,” Annals Oncology 12:
`1139-43 (2001)
`
`Ramanathan
`
`2075
`
`Ratain, M.J., “Phase II Oncology Trials:
`Let’s Be Positive,” Clin. Cancer Res.
`11(16): 5661-5662 (2005)
`
`Ratain 2005
`
`2076
`
`2077
`
`Raymond, E., et al., “CCI-779, A
`Rapamycin Analog With Antitumor
`Activity: A Phase I Study Utilizing A
`Weekly Schedule,” Proc. ASCO 19: 187a
`(Abs. 728) (2000)
`
`Raymond, E., et al., “CCI-779, An Ester
`Analogue Of Rapamycin That Interacts
`With PTEN/PI3 Kinase Pathways: A
`Phase I Study Utilizing A Weekly
`Intravenous Schedule,” Clinical Cancer
`Res. 6: 4549s (Abs. 414) (November
`Supplement) (2000)
`
`Raymond 2000a
`
`Raymond 2000b
`
`
`
`11
`
`
`
`2078
`
`2079
`
`2080
`
`2081
`
`2082
`
`Raymond, E., et al., “Safety And
`Pharmacokinetics Of Escalated Doses Of
`Weekly Intravenous Infusion Of CCI-
`779, A Novel mTOR Inhibitor, In
`Patients With Cancer,” J. Clin. Oncol.
`22(12): 2336-2347 (2004)
`
`Reubi, J.C., et al., “Absence Of
`Somatostatin Receptors In Human
`Exocrine Pancreatic Adenocarcinomas,”
`Gastroenterology 95(3): 760-763 (1988)
`
`Rowinsky, E.K. & Donehower, R.C.,
`“The Clinical Pharmacology And Use Of
`Antimicrotubule Agents In Cancer
`Chemotherapeutics,” Pharmac. Ther. 52:
`35-84 (1991)
`
`Drugs@FDA: FDA Approved Drug
`Products, Approval Date(s) And History,
`Sandostatin® (octreotide acetate),
`available at
`http://www.accessdata.fda.gov/scripts/cde
`r/daf/index.cfm?event=overview.process
`&ApplNo=019667 (accessed 12/8/2016)
`
`Serkova, N., et al., “Sirolimus, But Not
`The Structurally Related RAD
`(Everolimus), Enhances The Negative
`Effects Of Cyclosporine On
`Mitochondrial Metabolism In The Rat
`Brain,” British J. Pharmacol. 133: 875-
`885 (2001)
`
`2083
`
`Sklarin, N.T., et al., “A Phase I Trial And
`Pharmacokinetic Evaluation Of CI-980 In
`Patients With Advanced Solid Tumors,”
`Investig. New Drugs 15: 235-246 (1997)
`
`Raymond 2004
`
`Reubi
`
`Rowinsky &
`Donehower
`
`Sandostatin®
`(octreotide)
`Approval History
`
`Serkova
`
`Sklarin
`
`
`
`12
`
`
`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`Smith, M.C., et al., “OctreoTherTM:
`Ongoing Early Clinical Development Of
`A Somatostatin-Receptor-Targeted
`Radionuclide Antineoplastic Therapy,”
`Digestion 62(Supplement 1): 69-72
`(2000)
`
`Stadler, W.M., et al., “Flavopiridol, A
`Novel Cyclin-Dependent Kinase
`Inhibitor, In Metastatic Renal Cancer: A
`University Of Chicago Phase II
`Consortium Study,” J. Clin. Oncol. 18(2):
`371-375 (2000)
`
`Stolz, B., et al., “The Somatostatin
`Receptor-Targeted Radiotherapeutic
`[90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-
`SMT 487) Eradicates Experimental Rat
`Pancreatic CA 20948 Tumours,” Eur. J.
`Nuclear Med. 25(7): 668-674 (1998)
`
`Stolz, B., et al., “New Somatostatin
`Analogues For Radiotherapy Of
`Somatostatin Receptor Expressing
`Tumours,” Ital. J. Gastroenterol.
`Hepatol. 31(Supplement 2): S224-S226
`(1999)
`
`Stumm, M., et al., “Evaluation And
`Development Of An
`Immunohistochemical Procedure To
`Monitor Phospho-S6 As A Biomarker
`For The Activity Of RAD001,” Proc.
`Amer. Assoc. Cancer Res. 46(Supplement
`9): 109-110 (2005)
`
`Smith
`
`Stadler
`
`Stolz 1998
`
`Stolz 1999
`
`Stumm
`
`2089
`
`Sutent® FDA Supplemental Approval
`Letter, dated May 20, 2011
`
`Sutent® FDA
`Suppl. Approval
`Letter
`
`
`
`13
`
`
`
`2090
`
`Szkudelski, T., “The Mechanism Of
`Alloxan And Streptozotocin Action In B
`Cells Of The Rat Pancreas,” Physiol. Res.
`50: 536-546 (2001)
`
`Szkudelski
`
`2091
`
`Tarceva® (erlotinib) Prescribing
`Information (November 2, 2005)
`
`Tarceva®
`(erlotinib) Label
`
`2092
`
`2093
`
`2094
`
`2095
`
`2096
`
`Therasse, P., et al., “New Guidelines To
`Evaluate The Response To Treatment In
`Solid Tumors,” J. Natl. Cancer Inst.
`92(3): 205-216 (2000)
`
`Van Duyne, G.D., et al., “Atomic
`Structure Of The Rapamycin Human
`Immunophilin FKBP-12 Complex,” J.
`Am. Chem. Soc. 113: 7433-7434 (1991)
`
`Wang, D-G., et al., “Oncogene
`Expression In Gastroenteropancreatic
`Neuroendocrine Tumors: Implications
`For Pathogenesis,” Cancer 80(4): 668-
`675 (1997)
`
`World Health Organization, Chapter 10,
`“Tumours Of The Exocrine Pancreas,”
`Pathology And Genetics Of Tumors Of
`The Digestive System, pages 219-
`251(Hamilton, S.R. & Aaltonen, L.A.
`eds. 2000)
`
`World Health Organization, Chapter 4,
`“Tumours Of The Endocrine Pancreas,”
`World Health Organization
`Classification Of Tumours, Pathology
`And Genetics, Tumours Of Endocrine
`Organs, pages 183-208 (DeLellis, R.A. et
`al., eds. 2004)
`
`Therasse
`
`Van Duyne
`
`Wang 1997
`
`WHO 2000
`
`WHO 2004
`
`
`
`14
`
`
`
`2097
`
`“Wyeth Pharmaceuticals Announces
`Termination Of Phase 3 Clinical Program
`With Oral Temsirolimus In Women With
`Metastatic Breast Cancer Ongoing Phase
`3 Studies With I.V. Temsirolimus In
`Renal Cell Carcinoma And Mantle Cell
`Lymphoma Continue,” Wyeth
`Pharmaceuticals (March 16, 2006)
`
`Wyeth Press
`Release
`
`2098
`
`FDA Approval History for Zanosar®
`(streptozocin) (accessed 5/8/2017)
`
`Zanosar®
`(streptozocin)
`Approval History
`
`2099
`
`2100
`
`2101
`
`2102
`
`Kulke, M., et al., “Results Of A Phase II
`Study With Sunitinib Malate (SU11248)
`In Patients (pts) With Advanced
`Neuroendocrine Tumours (NETs),” Eur.
`J. Cancer 3(2): 204 (Abs. 718) (abstract
`book) (2005)
`
`Srkalovic, G., et al., “Evaluation Of
`Receptors For Somatostatin In Various
`Tumors Using Different Analogs,” J.
`Clin. Endocrinology & Metabolism
`70(3): 661-669 (1990)
`
`Eisen, T., et al., “Sorafenib In Advanced
`Melanoma: A Phase II Randomised
`Discontinuation Trial Analysis,” British
`J. Cancer 95(5): 581-586 (2006)
`
`Pacey, S., et al., “Efficacy And Safety Of
`Sorafenib In A Subset Of Patients With
`Advanced Soft Tissue Sarcoma From A
`Phase II Randomized Discontinuation
`Trial,” Invest. New Drugs 29: 481-488
`(2011)
`
`Kulke 2005
`
`Srkalovic
`
`
`
`
`
`
`
`15
`
`
`
`2103
`
`2104
`
`2105
`
`2106
`
`2107
`
`Ratain, M.J., et al., “Phase II Placebo-
`Controlled Randomized Discontinuation
`Trial Of Sorafenib In Patients With
`Metastatic Renal Cell Carcinoma,” J.
`Clin. Oncology 24(16): 2505-2512 (2006)
`
`Ratain, M.J., “Phase II Studies Of
`Modern Drugs Directed Against New
`Targets: If You Are Fazed, Too, Then
`Resist RECIST,” J. Clin. Oncology
`22(22): 4442-4445 (2004)
`
`Excerpts of Transcript of Deposition of
`M. Ratain, Novartis v. Breckenridge,
`Roxane and Par (C.A. Nos. 14-1043-
`RGA, 14-1196-RGA and 14-1289-RGA)
`(D. Del. Apr. 11, 2016), Pages 1-5, 93-
`95, 198, 349-350
`
`Excerpts of Transcript of Deposition of
`M. Ratain, Novartis v. Par (Inter Partes
`Review No. 2016-00084) (Pat. Tr. App.
`Bd. December 16, 2016), Pages 1-5, 119-
`120, 141
`
`Ponnusamy, S., et al., “Deciphering The
`Inactivation Of Human Pancreatic α-
`Amylase, An Anti-Diabetic Target, By
`Bisdemethoxycurcumin, A Small
`Molecule Inhibitor, Isolated From
`Curcuma longa,” Nat. Prods. J. 3(1):15-
`25 (2013)
`
`2108
`
`Yoshikumi, Y.K., et al., “Up Regulation
`Of JAM 1 In AR42J Cells Treated With
`Activin A And Betacellulin And The
`Diabetic Regenerating Islets,” Endocrine
`J. 4:757-65 (2008)
`
`
`
`Ratain 2004
`
`Ratain Dep. Tr. I
`
`Ratain Dep. Tr. II
`
`
`
`
`
`
`
`16
`
`
`
`2109
`
`2110
`
`Arnold, R., et al., Chapter
`15,“Neuroendocrine Gastro-Entero-
`Pancreatic (GEP) Tumors,”
`Gastrointestinal And Liver Tumors, pages
`195-233 (Scheppach, W., et al., eds.
`2004)
`
`National Cancer Institute, National
`Institutes of Health, U.S. Department of
`Health and Human Services, 2005 Fact
`Book (2005), available at
`https://www.cancer.gov/about-
`nci/budget/fact-book/archive/2005-fact-
`book.pdf (accessed 08/25/2017)
`
`2111
`
`Transcript Of The August 28, 2017
`Deposition Of Mark J. Ratain
`
`2112
`(served
`but not
`filed)
`
`National Cancer Institute, National
`Institutes of Health, U.S. Department of
`Health and Human Services, 2004 Fact
`Book (2004), available at
`https://www.cancer.gov/about-
`nci/budget/fact-book/archive/2005-fact-
`book.pdf (accessed 09/05/2017)
`
`2113
`(served
`but not
`filed)
`
`Transcript of Deposition of M. Ratain,
`Novartis v. Par (Inter Partes Review No.
`2016-00084) (Pat. Tr. App. Bd.
`December 16, 2016)
`
`2114
`(served
`but not
`filed)
`
`Torisel® (temsirolimus) Label (July
`2017), available at
`https://www.accessdata.fda.gov/drugsatfd
`a_docs/label/2016/022088s019lbl.pdf
`(accessed 06/01/2017)
`
`
`
`17
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2115
`(served
`but not
`filed)
`
`Afinitor® (everolimus) Label (June
`2016), available at
`https://www.accessdata.fda.gov/drugsatfd
`a_docs/label/2016/022334s038lbl.pdf
`(accessed 06/01/2017)
`
`2116
`
`2117
`
`Email chain between Andrew Kellogg,
`Supervisory Paralegal, USPTO and Jared
`L. Stringham, Attorney, Fitzpatrick,
`Cella, Harper & Scinto (Sept. 20-25,
`2017)
`
`December 14, 2017 Trial Opinion in
`Novartis Pharm. Corp. v. West-Ward
`Pharm. Int’l Ltd., No. 15-cv-474-RGA
`(D. Del.) (D.I. 100)
`
`
`
`
`
`
`
`
`
`18
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing Patent Owner’s Exhibit List 10 was
`
`served on December 19, 2017 by causing it to be sent by email to counsel for
`
`Petitioners at the following email addresses:
`
`
`Daniel G. Brown (daniel.brown@lw.com)
`
`Jonathan M. Strang (jonathan.strang@lw.com)
`
`Brenda L. Danek (brenda.danek@lw.com)
`
`Kevin Laurence (klaurence@lpiplaw.com)
`
`Matthew Phillips (mphillips@lpiplaw.com)
`
`Tyler C. Liu (tliu@agpharm.com)
`
`Keith A. Zullow (kzullow@goodwinprocter.com)
`
`Marta E. Delsignore (mdesignore@goodwinprocter.com)
`
`
`
`Dated: December 19, 2017
`
`
`
`
`
`
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`19
`
`